Balanced news tone
News Sentiment
ARDX sentiment intelligence
Ardelyx Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
52
Balanced news tone
64 relevant articles
News tone and price action are not far from neutral.
82/100 classification confidence.
directly relevant articles
high-authority source matches
+0.2% over one week, -7.2% over four weeks, trend inactive, and near fair-value range.
Lobbying Update: $500,000 of ARDELYX INC. lobbying was just disclosed
Market Reaction
Balanced read
News tone and price action are not far from neutral.
Primary event
Market update
82/100 classification
One-week reaction
0.2%
Price digesting
Trend fit
Trend inactive
-7.2% over four weeks
Fair value
-8.0%
Near fair-value range
Sentiment Mix
Positive, neutral, negative
Positive
14
Neutral
45
Negative
5
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
Quiver Quantitative
Direct company coverage
Lobbying Update: $500,000 of ARDELYX INC. lobbying was just disclosed
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 15 Jul 2026 23:13
- Source
- Quiver Quantitative
StockStory
Industry context
Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 15 Jul 2026 07:00
- Source
- StockStory
Stock Traders Daily
Direct company coverage
Trading the Move, Not the Narrative: (ARDX) Edition
This article provides an analysis of Ardelyx Inc. (ARDX), highlighting weak near and mid-term sentiment that could challenge its long-term positive outlook. It presents institutional trading strategies, including position trading, momentum breakout, and risk hedging, along with d
- Tone
- Negative 38/100
- Event
- Guidance
- Published
- 15 Jul 2026 04:30
- Source
- Stock Traders Daily
Stocktwits
Direct company coverage
Dow, S&P 500, Nasdaq Futures Rise As Traders Eye Supreme Court Tariff Verdict, GDP Data: Why GRAL, RIG, CADL, CELH, ARDX Are Trending
- Tone
- Neutral 50/100
- Event
- Macro sensitivity
- Published
- 14 Jul 2026 21:58
- Source
- Stocktwits
Market source
Industry context
Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 13 Jul 2026 12:30
- Source
- Market source
The Globe and Mail
Direct company coverage
Ardelyx Secures New $50 Million Term F Loan
Ardelyx (ARDX) has secured a new $50 million Term F Loan under its existing agreement with SLR Investment Corp. and other lenders to support general corporate purposes and strategic initiatives. The loan matures on July 1, 2030, with interest-only payments permitted until maturit
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 08 Jul 2026 01:40
- Source
- The Globe and Mail
Stock Titan
Direct company coverage
Ardelyx (NASDAQ: ARDX) draws $50M Term F loan maturing in 2030
Ardelyx, Inc. (NASDAQ: ARDX) has secured a new $50.0 million Term F Loan under its existing loan and security agreement with SLR Investment Corp. and other lenders, with the funding received on June 29, 2026. This loan matures on July 1, 2030, and allows for interest-only payment
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 02 Jul 2026 20:39
- Source
- Stock Titan
TradingView
Direct company coverage
Price to sales forward of Ardelyx, Inc. – NASDAQ:ARDX
The article provides a financial overview of Ardelyx, Inc. (NASDAQ: ARDX), specifically focusing on its price-to-sales forward metric. It details the company's stock market presence on Nasdaq and offers navigation to various financial tools and data through the TradingView platfo
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 02 Jul 2026 12:09
- Source
- TradingView
TradingView
Direct company coverage
Price to book forward of Ardelyx, Inc. – NASDAQ:ARDX
This article provides financial information for Ardelyx, Inc. (NASDAQ: ARDX), specifically focusing on its "Price to book forward" metric. The content appears to be a stub or a section from a financial data platform, highlighting the company's stock information and financial over
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 02 Jul 2026 05:10
- Source
- TradingView
TradingView
Direct company coverage
Price to earnings forward of Ardelyx, Inc. – TRADEGATE:41X
This article provides limited financial information for Ardelyx, Inc. (TRADEGATE:41X), focusing on its forward price-to-earnings ratio. The content indicates that market data is closed with no trades, and the report offers a brief overview of financial metrics without specific va
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 01 Jul 2026 15:09
- Source
- TradingView
Simply Wall Street
Direct company coverage
Ardelyx (ARDX) Faces New Medicare Rules For Xphozah After Court Ruling
A recent U.S. federal appellate court ruling has determined that Ardelyx's drug Xphozah will be included in Medicare's End Stage Renal Disease (ESRD) bundled payment system, rather than being reimbursed separately. This decision concludes a long-standing legal dispute and will al
- Tone
- Negative 36/100
- Event
- Market update
- Published
- 01 Jul 2026 09:39
- Source
- Simply Wall Street
Moomoo
Direct company coverage
Jefferies Maintains Ardelyx(ARDX.US) With Buy Rating, Maintains Target Price $15
Jefferies has reiterated its Buy rating on Ardelyx (ARDX.US) and maintained its target price at $15. This indicates a continued positive outlook from the firm regarding Ardelyx's stock performance.
- Tone
- Positive 74/100
- Event
- Analyst action
- Published
- 26 Jun 2026 19:40
- Source
- Moomoo
Seeking Alpha
Direct company coverage
Ardelyx falls after setback in Xphozah appeal (ARDX:NASDAQ)
Ardelyx shares declined approximately 6% after losing an appeal against the Health and Human Services Department. The appeal concerned a Medicare decision that eliminated Part D coverage for Ardelyx's kidney disease therapy, Xphozah. This setback stems from a lawsuit filed in Jul
- Tone
- Negative 28/100
- Event
- Regulatory and legal
- Published
- 26 Jun 2026 18:40
- Source
- Seeking Alpha
TradingView
Direct company coverage
Ardelyx, Inc. Actuals & Estimates (NASDAQ:ARDX)
Ardelyx, Inc. (NASDAQ:ARDX) stock has seen a decrease of -8.42% in the past 24 hours, with a current price of 5.55 USD, though it has increased by 52.89% over the last year. Analysts provide a future price forecast for ARDX ranging from a maximum estimate of 19.00 USD to a minimu
- Tone
- Neutral 50/100
- Event
- Guidance
- Published
- 26 Jun 2026 06:40
- Source
- TradingView
TradingView
Direct company coverage
Ardelyx, Inc. Actuals & Estimates (FWB:41X)
This article provides financial actuals and estimates for Ardelyx, Inc. (FWB:41X), covering its income statement, balance sheet, and cash flow. It includes analyst forecasts, historical price data, earnings reports, revenue, net income, and information about the company's employe
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 25 Jun 2026 20:39
- Source
- TradingView
Simply Wall Street
Direct company coverage
Is Ladenburg’s IBSRELA Focus Quietly Reframing Ardelyx’s (ARDX) Risk‑Reward Story?
Investment bank Ladenburg initiated coverage on Ardelyx (ARDX), highlighting the growing demand for IBSRELA and continued commercial success of XPHOZAH, aligning with management's ambitious long-term revenue projections. This new coverage reinforces IBSRELA's central role as a ke
- Tone
- Positive 70/100
- Event
- Earnings
- Published
- 25 Jun 2026 18:39
- Source
- Simply Wall Street
TradingKey
Direct company coverage
Ardelyx Inc (ARDX) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Ardelyx Inc (ARDX), detailing its current price momentum score, support and resistance levels, and indicator and moving average signals. It notes ARDX has a price momentum score of 8.91 and is trading between a resistance of $6.66 and
- Tone
- Positive 67/100
- Event
- Market update
- Published
- 24 Jun 2026 07:40
- Source
- TradingKey
The Globe and Mail
Direct company coverage
Ardelyx Stock Up 70%: What to Know About This $490,000 Insider Transaction
Ardelyx Chief Patient Officer Laura Williams sold 81,898 shares of Common Stock for approximately $490,000, reducing her direct holdings by 17.8% after the stock rallied 70% over the past year. The transaction, executed under a 10b5-1 trading plan, involved the exercise of stock
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 23 Jun 2026 22:39
- Source
- The Globe and Mail
Market source
Direct company coverage
What’s Fueling Optimism Around Ardelyx, Inc. (ARDX)’s Sales and Pipeline?
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 23 Jun 2026 07:00
- Source
- Market source
Investing.com South Africa
Direct company coverage
Form 4 Ardelyx Inc For: 22 June By Investing.com
This article from Investing.com is a brief announcement regarding a Form 4 filing for Ardelyx Inc., dated June 22. It provides no further details beyond the filing's existence and is accompanied by various financial market data and unrelated news headlines.
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 23 Jun 2026 05:39
- Source
- Investing.com South Africa
MT Newswires
Direct company coverage
Ardelyx Insider Sold Shares Worth $490,487, According to a Recent SEC Filing
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 22 Jun 2026 20:13
- Source
- MT Newswires
Investing.com Nigeria
Direct company coverage
Ardelyx chief patient officer sells $490k in stock By Investing.com
Laura A. Williams, Chief Patient Officer at Ardelyx, Inc. (NASDAQ: ARDX), sold 81,898 shares of company stock for approximately $490,487 and exercised options for 31,000 shares valued at $30,690, all under a pre-arranged 10b5-1 trading plan. The transactions occurred on June 18,
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 22 Jun 2026 20:10
- Source
- Investing.com Nigeria
Stock Titan
Direct company coverage
Ardelyx (ARDX) Chief Patient Officer sells shares, exercises 31,000 options
Ardelyx, Inc.'s Chief Patient Officer, Laura A. Williams, sold 81,898 shares of common stock at a weighted average price of $5.989 per share. This sale was conducted under a Rule 10b5-1 trading plan adopted on March 19, 2026. Concurrently, Williams exercised stock options to acqu
- Tone
- Negative 38/100
- Event
- Market update
- Published
- 22 Jun 2026 20:10
- Source
- Stock Titan
Investing.com
Direct company coverage
Ardelyx chief patient officer sells $490k in stock
Ardelyx Inc.'s Chief Patient Officer, Laura A. Williams, sold approximately $490,487 worth of company stock while simultaneously exercising stock options valued at $30,690. These transactions occurred on June 18, 2026, under a pre-arranged 10b5-1 trading plan. The article also no
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 22 Jun 2026 17:10
- Source
- Investing.com
Stock Titan
Direct company coverage
Ardelyx (ARDX) director receives RSUs and stock options as compensation
Ardelyx, Inc. director Muna Bhanji received 26,455 restricted stock units (RSUs) and options for 39,715 shares with an exercise price of $5.6700 per share, expiring on June 16, 2036. These equity grants were part of the company's Non-Employee Director Compensation Program. Follow
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 19 Jun 2026 16:11
- Source
- Stock Titan
Stock Titan
Direct company coverage
Ardelyx (ARDX) director receives 26,455 RSUs and 39,715-share option
Ardelyx director Richard J. Rodgers received new equity awards as part of the company's Non-Employee Director Compensation Program. He was granted 26,455 restricted stock units (RSUs) and a stock option for 39,715 shares with an exercise price of $5.67 per share. These awards inc
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 19 Jun 2026 05:10
- Source
- Stock Titan
TradingKey
Direct company coverage
Ardelyx Inc (ARDX) Earnings Forecast: Future EPS & Revenue Growth Estimates
Ardelyx Inc (ARDX) has an earnings forecast score of 9.27, placing it highly within the Biotechnology & Medical Research industry. Analysts have a strong buy rating for ARDX, with an average price target of $11.00 and expectations for positive revenue growth. The company's EPS fo
- Tone
- Positive 75/100
- Event
- Earnings
- Published
- 19 Jun 2026 04:40
- Source
- TradingKey
TradingKey
Direct company coverage
Ardelyx Inc (ARDX) Institutional Confidence
Ardelyx Inc (ARDX) currently holds an institutional shareholding score of 7.00, placing it 81st in the Biotechnology & Medical Research industry. The institutional shareholding proportion is 71.25%, showing a 7.13% decrease quarter-over-quarter. Steven Cohen is the largest instit
- Tone
- Positive 61/100
- Event
- Market update
- Published
- 19 Jun 2026 04:09
- Source
- TradingKey
Stock Titan
Direct company coverage
Equity grants to Ardelyx (ARDX) director under compensation program
Ardelyx director David M. Mott received equity awards through the company’s Non-Employee Director Compensation Program. These awards included 46,737 shares of common stock at no cash cost and a stock option for 39,715 shares with an exercise price of $5.67, expiring in 2036. The
- Tone
- Neutral 50/100
- Event
- Balance sheet
- Published
- 19 Jun 2026 03:40
- Source
- Stock Titan
Stock Titan
Direct company coverage
Ardelyx (ARDX) director granted RSUs and 39,715-share stock option
Ardelyx director Merdad Parsey was granted 26,455 restricted stock units (RSUs) and a stock option for 39,715 shares at an exercise price of $5.67, under the company's Non-Employee Director Compensation Program. These awards are equity compensation, not open-market trades. Follow
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 Jun 2026 21:39
- Source
- Stock Titan